Further experiments on the therapy of leukemia L1210 with rabbit antiserum prepared against whole leukemia cells have confirmed the mild effectiveness of this agent, which gave no long-term survivors. In contrast, therapy with Mycobacterium bovis (strain Bacillus Calmette-Guérin) gave some long-term survivors, when used under optimal conditions of route and of other still undefined factors, which appear to include the dosage, viability, and strain of BCG.

Mice bearing leukemia L1210 show a strong depression of primary antibody response to sheep erythrocytes. BCG does not increase the primary γG antibody response to sheep erythrocytes.

As a sensitive indicator of leukemia cell damage, it has been possible to use whole-body counting of mice given injections of as few as 100,000 iododeoxyuridine-125I-labeled L1210 cells. This makes it possible to use labeled cells in the standard L1210 assay of the Cancer Chemotherapy National Service Center.


This investigation was supported by USPHS Research Grant CA-04469 from the National Cancer Institute.

This content is only available via PDF.